A Phase2 Study of Platinum Doublet and Bevacizumab followed by Bevacizumab and Pemetrexed maintenance for Non-squarmous Non Small Cell Lung Cancer Patients

A Phase2 Study of Platinum Doublet and Bevacizumab followed by Bevacizumab and Pemetrexed maintenance for Non-squarmous Non Small Cell Lung Cancer Patients - Platinum Doublet and Bevacizumab followed by Bevacizumab and Pemetrexed maintenance for Non-squarmous Non Small Cell Lung Cancer Patients

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005764

Enrollment

Registered

2011-06-16

Start date

2011-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-squarmous Non Small Cell Lung Cancer(non-pretreated patient)

Interventions

Pulatinum doublet and Bevacizumab followed by maintenance Bevacizumab and Pemetrexed until Clinical disease progression

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Histologically or cytologically proven non small cell lung cancer(non-squarmous cell lung cancer) 2)Stage 3B/4 3)With evaluated and measured lesion according to RECIST(Ver.1.1) 4)Age 20-75 5)ECOG PS0-1 6)Adequate functions of major organs 7)Written informed concent

Exclusion criteria

Exclusion criteria: 1)Previous hemopotysis (2.5ml) 2)Brain metastasis. 3)Any operation, biopsy associated with section, or any saturation of wounds within 4 weeks before enrollment. 4)Untreated traumatic bone fracture. 5)Consolidated or history of gastric perforation within 1 year before enrollment. 6)Uncontrollable peptic ulcer. 7)Tendency to bleed, or coagulation defect. 8)Treated with antithrombotic drugs within 10 days before enrollment. 9)Chronic inflammatory disease requiring anti-platelet agent. 10)History of interstitial lung disease. 11)Uncontrollable pleural effusion or ascites. 12)Uncontrollable heart disease and/or hypertension. 13)Cardiac infraction or cerebral infraction within 6 months before enrollment. 14)Have another active malignancy. 15)Severe infection or malnutrition. 16)Severe drug allergy. 17)In pregnancy, during breast feeding, or possibility of pregnancy. 18)Invasion to major vessel. 19)Cavitation of tumor. 20)History of chest irradiation (excluding if radiation field does not cover the primary tumor). 21)Any patient who is judged to be inappropriate for participation.

Design outcomes

Primary

Measure	Time frame
Progression Free Survival	—

Secondary

Measure	Time frame
Safety Overall Survival Rate of shift to maintenance	—

Countries

Japan

Contacts

Public ContactYoshinobu Iwasaki

Kyoto Prefectural University of Medicine Pulmonary Medicine

yiwasaki@koto.kpu-m.ac.jp075-251-5513

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026